FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models and favorable therapeutic windows in long-term toxicology studies. Laekna is actively seeking partners to accelerate clinical development.
News Link: https://www.businesswire.com/news/home/20250303151589/en/Laekna-Announces-IND-Approval-of-LAE120-a-Novel-USP1-Inhibitor-for-Treatment-of-Advanced-Solid-Tumors-by-FDA
Leave a Reply